Literature DB >> 23054313

Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis.

Michael Staehler1, Matthias Sauter, Andreas Helck, Ulrich Linsenmaier, Lutz Weber, Karin Mayer, Michael Fischereder.   

Abstract

PURPOSE: Renal angiomyolipoma in patients with tuberous sclerosis can cause life-threatening bleeding. Embolization or resection is recommended, but either intervention may result in substantial loss of renal function. Recently, regression of angiomyolipoma size has also been achieved with mTOR inhibitor therapy, but recurrent lesion growth after treatment cessation has to be expected. This is the first report on a multimodal therapeutic approach facilitating a nephron-sparing, definitive resection.
METHODS: Three patients with renal angiomyolipoma not amenable to nephron-sparing surgery were treated with sirolimus aiming trough levels of 4-8 ng/ml. Treatment was well tolerated.
RESULTS: mTOR inhibitor treatment resulted in a regression of angiomyolipoma volume by 38-95 %. Thereafter, nephron-sparing angiomyolipoma resection conserved normal renal function.
CONCLUSION: Neoadjuvant use of mTOR inhibitor pretreatment may represent a novel approach facilitating nephron-sparing resection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054313     DOI: 10.1007/s11255-012-0292-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  22 in total

1.  Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.

Authors:  Ralf Wienecke; Ingrid Fackler; Ulrich Linsenmaier; Karin Mayer; Thomas Licht; Matthias Kretzler
Journal:  Am J Kidney Dis       Date:  2006-09       Impact factor: 8.860

2.  Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex.

Authors:  Jarrod M Williams; John M Racadio; Neil D Johnson; Lane F Donnelly; John J Bissler
Journal:  Am J Kidney Dis       Date:  2006-01       Impact factor: 8.860

3.  Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis.

Authors:  Elahna Paul; Elizabeth Thiele
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

4.  Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms.

Authors:  Raouf M Seyam; Nabil K Bissada; Said A Kattan; Alaa A Mokhtar; Muhammad Aslam; Wahib E Fahmy; Walid A Mourad; Ali A Binmahfouz; Hassan M Alzahrani; Kamal A Hanash
Journal:  Urology       Date:  2008-09-21       Impact factor: 2.649

5.  Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis.

Authors:  Cristina Cabrera López; Teresa Martí; Violeta Catalá; Ferrán Torres; Silvia Mateu; Jose Ballarín Castán; Roser Torra Balcells
Journal:  Nefrologia       Date:  2011       Impact factor: 2.033

6.  Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors.

Authors:  S K Rakowski; E B Winterkorn; E Paul; D J R Steele; E F Halpern; E A Thiele
Journal:  Kidney Int       Date:  2006-09-27       Impact factor: 10.612

7.  Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated.

Authors:  Prasanna Sooriakumaran; Philippa Gibbs; Geoffrey Coughlin; Virginia Attard; Frances Elmslie; Christopher Kingswood; Jeremy Taylor; Cathy Corbishley; Uday Patel; Christopher Anderson
Journal:  BJU Int       Date:  2009-06-02       Impact factor: 5.588

8.  An epidemiological study of renal pathology in tuberous sclerosis complex.

Authors:  Finbar J O'Callaghan; Michael J Noakes; Christopher N Martyn; John P Osborne
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

9.  Renal angiomyolipoma: long-term results following selective arterial embolization.

Authors:  Jacob Ramon; Uri Rimon; Alex Garniek; Gil Golan; Paul Bensaid; Noam D Kitrey; Andrei Nadu; Zohar A Dotan
Journal:  Eur Urol       Date:  2008-04-18       Impact factor: 20.096

10.  Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

Authors:  D Mark Davies; Petrus J de Vries; Simon R Johnson; Deborah L McCartney; Jane A Cox; Andreas L Serra; Peter C Watson; Christopher J Howe; Tim Doyle; Kate Pointon; Justin J Cross; Anne E Tattersfield; J Chris Kingswood; Julian R Sampson
Journal:  Clin Cancer Res       Date:  2011-04-27       Impact factor: 12.531

View more
  6 in total

Review 1.  Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

Authors:  Daniel Fantus; Natasha M Rogers; Florian Grahammer; Tobias B Huber; Angus W Thomson
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

Review 2.  Rapamycin and rapalogs for tuberous sclerosis complex.

Authors:  Teguh H Sasongko; Nur Farrah Dila Ismail; Zamh Zabidi-Hussin
Journal:  Cochrane Database Syst Rev       Date:  2016-07-13

3.  Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis.

Authors:  Guang Yang; Lu Yang; Xiaofan Yang; Xiuyu Shi; Jing Wang; Yujie Liu; Jun Ju; Liping Zou
Journal:  Exp Ther Med       Date:  2014-11-27       Impact factor: 2.447

4.  Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition.

Authors:  Thierry Krummel; Julien Garnon; Hervé Lang; Afshin Gangi; Thierry Hannedouche
Journal:  BMC Urol       Date:  2014-09-25       Impact factor: 2.264

5.  Leiomyomatosis-like lymphangioleiomyomatosis: A case report of the colonic manifestation of tuberous sclerosis.

Authors:  Ergin Erginoz; Halit Eren Taskin; Gokce Hande Cavus; Abdullah Kagan Zengin
Journal:  Medicine (Baltimore)       Date:  2021-12-17       Impact factor: 1.817

6.  Familial genetic tuberous sclerosis complex associated with bilateral giant renal angiomyolipoma: A case report.

Authors:  Lina Wang; Dawei Ni; Lin Zhong; Jianbo Wang
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.